Sadeghi Mahmoud, Daniel Volker, Naujokat Cord, Schmidt Jan, Mehrabi Arianeb, Zeier Martin, Opelz Gerhard
Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
Clin Transplant. 2007 Jul-Aug;21(4):449-59. doi: 10.1111/j.1399-0012.2007.00665.x.
We found recently that patients with good graft outcome showed higher IFN-gamma and IL-2, and lower IL-10 plasma levels late post-transplant than early post-transplant. In this retrospective study, we compared cytokine plasma levels in 33 symptom-free outpatients with those of 33 renal transplant recipients with early acute rejection (EAR), 29 with chronic rejection (CR), and 34 healthy controls (HC) to assess whether there is evidence for Th1 activation late post-transplant in patients with good graft outcome. Cytokines were measured pre-transplant, one wk, one month, six months, one yr, and two yr after transplantation. Twelve and 24 months post-transplant, IFN-gamma plasma levels were significantly higher (p = 0.001; p = 0.001, respectively) and IL-4 plasma levels significantly lower (p = 0.028; p = 0.003, respectively) in patients with stable graft function than those in controls. Six, 12, and 24 months post-transplant, patients with stable graft function had similar IFN-gamma and IL-4 plasma levels as patients with successfully treated EAR (p = n.s.), and higher IFN-gamma (p = 0.013; p = 0.001; p = 0.0005, respectively) and lower IL-4 (p = 0.007; p = 0.417; p = 0.0001, respectively) plasma levels than patients with CR. These data suggest that increased plasma IFN-gamma and decreased plasma IL-4 late post-transplant might be involved in the induction of mechanisms that facilitate good long-term graft outcome.
我们最近发现,移植效果良好的患者在移植后期血浆中干扰素-γ(IFN-γ)和白细胞介素-2(IL-2)水平高于移植早期,而白细胞介素-10(IL-10)水平则低于移植早期。在这项回顾性研究中,我们比较了33名无症状门诊患者、33名发生早期急性排斥反应(EAR)的肾移植受者、29名发生慢性排斥反应(CR)的肾移植受者以及34名健康对照者(HC)的细胞因子血浆水平,以评估移植效果良好的患者在移植后期是否存在Th1激活的证据。在移植前、移植后1周、1个月、6个月、1年和2年测量细胞因子水平。移植后12个月和24个月,移植功能稳定的患者血浆IFN-γ水平显著高于对照组(分别为p = 0.001;p = 0.001),血浆IL-4水平显著低于对照组(分别为p = 0.028;p = 0.003)。移植后6个月、12个月和24个月,移植功能稳定的患者血浆IFN-γ和IL-4水平与EAR治疗成功的患者相似(p = 无显著性差异),且血浆IFN-γ水平高于CR患者(分别为p = 0.013;p = 0.001;p = 0.0005),血浆IL-4水平低于CR患者(分别为p = 0.007;p = 0.417;p = 0.0001)。这些数据表明,移植后期血浆IFN-γ水平升高和血浆IL-4水平降低可能参与了促进长期良好移植效果机制的诱导过程。